CompanyGraph
Kontour Xi'an Medical Technology Co. Ltd.
688314 · SSE · China
kontourmedical.comFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 10.05: safe zone
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.95%Below 5Y avg (1.26%)
Annual Rate
CNY 0.30Paid semi-annual
Payout Ratio
50.0%Sustainable
Payback Period
64.3 yr
Last Ex-Dividend
Sep 16, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
2.58BCNY385.64M · vs all stocks (USD)
Trailing P/E
30.11xvs Medical Devices peers
Revenue (TTM)
351.72MCNY52.50M · vs all stocks (USD)
Profit Margin
24.19%vs Medical Devices peers
Beta
-0.0490xvs all stocks
52-Week Change
-11.52%vs all stocks
Forward Annual Dividend Yield
0.95%vs all stocks
Market Capitalization
2.58BCNY385.64M · vs all stocks (USD)
Enterprise Value
2.20BCNY327.67M · vs all stocks (USD)
Trailing P/E
30.11xvs Medical Devices peers
Price to Sales (TTM)
7.27xvs Medical Devices peers
Price to Book (MRQ)
3.36xvs Medical Devices peers
Enterprise to Revenue
6.24xvs Medical Devices peers
Enterprise to EBITDA
18.71xvs Medical Devices peers
Gross Margin
77.82%vs Medical Devices peers
Profit Margin
24.19%vs Medical Devices peers
Operating Margin
28.32%vs Medical Devices peers
Return on Assets (TTM)
7.25%vs Medical Devices peers
Return on Equity (TTM)
11.65%vs Medical Devices peers
Revenue (TTM)
351.72MCNY52.50M · vs all stocks (USD)
Revenue per Share (TTM)
4.30CNYUpdated Sep 22, 2026Quarterly Revenue Growth
10.80%vs Medical Devices peers
Gross Profit (TTM)
271.74MCNY40.56M · vs all stocks (USD)
EBITDA (TTM)
117.93MCNY17.60M · vs all stocks (USD)
Net Income (TTM)
85.10MCNY12.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-8.80%vs Medical Devices peers
Operating Cash Flow (TTM)
115.46MCNY17.23M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
24.51MCNY3.66M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3000CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
0.95%vs all stocks
Trailing Annual Dividend Rate
0.4700CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.49%vs all stocks
5-Year Average Dividend Yield
1.26%vs all stocks
Payout Ratio
50.00%vs Medical Devices peers
Minority Interest (Equity)
6.28MCNYFY2025 · Dec 31, 2025Revenue
351.08MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
74.82MCNYFY2025 · Dec 31, 2025Gross Profit
276.26MCNYFY2025 · Dec 31, 2025Operating Income
125.58MCNY18.75M · vs all stocks (USD)
Pre-tax Income
115.52MCNYFY2025 · Dec 31, 2025Income Tax Expense
17.77MCNYFY2025 · Dec 31, 2025Net Income
97.75MCNYFY2025 · Dec 31, 2025EBIT
117.84MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
139.01MCNYFY2025 · Dec 31, 2025Research & Development
25.64MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
59.26MCNYFY2025 · Dec 31, 2025Other Operating Expenses
6.25MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.32MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
97.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
955.22KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
74.61MCNYFY2025 · Dec 31, 2025Free Cash Flow
23.23MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
373.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
97.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.20MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-15.56MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.78MCNYFY2025 · Dec 31, 2025Capital Expenditures
-51.39MCNYFY2025 · Dec 31, 2025Net Acquisitions
-46.84MCNYFY2025 · Dec 31, 2025Purchase of Investments
-15.00MCNYFY2025 · Dec 31, 2025Sale of Investments
2.21MCNYFY2025 · Dec 31, 2025Other Investing Activity
-5.35MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-116.37MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
30.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
0.00CNYFY2025 · Dec 31, 2025Common Dividends Paid
-32.78MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.19MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.97MCNYFY2025 · Dec 31, 2025Shares Outstanding
81.24MSharesUpdated Sep 22, 2026Float Shares
29.27MSharesUpdated Sep 22, 2026% Held by Insiders
63.91%vs all stocks
% Held by Institutions
1.09%vs all stocks
Total Cash (MRQ)
372.66MCNY55.63M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.57CNYUpdated Sep 22, 2026Total Debt (MRQ)
94.83MCNY14.16M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1260xvs Medical Devices peers
Current Ratio (MRQ)
4.36xvs Medical Devices peers
Book Value per Share (MRQ)
9.31CNYUpdated Sep 22, 2026Total Assets
909.16MCNY135.71M · vs all stocks (USD)
Total Current Assets
443.39MCNYFY2025 · Dec 31, 2025Total Liabilities
185.12MCNYFY2025 · Dec 31, 2025Total Non-current Assets
465.77MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
80.05MCNYFY2025 · Dec 31, 2025Total Current Liabilities
105.07MCNYFY2025 · Dec 31, 2025Cash
373.28MCNYFY2025 · Dec 31, 2025Cash Equivalents
790.06KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
374.07MCNYFY2025 · Dec 31, 2025Accounts Receivable
17.94MCNYFY2025 · Dec 31, 2025Inventory
32.62MCNYFY2025 · Dec 31, 2025Accounts Payable
23.08MCNYFY2025 · Dec 31, 2025Short-term Debt
47.17MCNYFY2025 · Dec 31, 2025Other Current Liabilities
409.53KCNYFY2025 · Dec 31, 2025Long-term Debt
40.58MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
77.23KCNYFY2025 · Dec 31, 2025Common Stock (Book)
81.24MCNYFY2025 · Dec 31, 2025Retained Earnings
272.64MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
724.04MCNY108.08M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
28.00CNYUpdated Sep 22, 202652-Week High
58.60CNYUpdated Sep 22, 202652-Week Change
-11.52%vs all stocks
Beta
-0.0490xvs all stocks
50-Day MA
31.97CNYUpdated Sep 22, 2026200-Day MA
38.37CNYUpdated Sep 22, 2026Avg 10-Day Volume
807.41KSharesUpdated Sep 22, 2026Avg 30-Day Volume
765.39KSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.04CNYUpdated Sep 22, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.11Receivables vs revenue divergence: 2.28
Financial Health
Altman Z-Score 10.05: safe zoneNotable
Altman Z-Score: 10.05
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Central Depository Services (India) Ltd.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Kingnet Network Co., Ltd.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
United States Lime & Minerals Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthCash Elevated Relative to Current Liabilities and Total AssetsRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin